UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       Pursuant to Section 13 OR 15(d) of
                       The Securities Exchange Act of 1934

                                September 9, 2004
                Date of Report (Date of earliest event reported)


-------------------------------------------------------------------------------
                                 ANTIGENICS INC
             (Exact name of registrant as specified in its charter)


-------------------------------------------------------------------------------
          DELAWARE               000-29089                06-1562417
(State or other jurisdiction    (Commission             (IRS Employer
       of incorporation)        File Number)         Identification No.)



          630 Fifth Avenue, Suite 2100
               New York, NY 10111                                    10111
    (Address of principal executive offices)                      (Zip Code)




                                  212-994-8200
              (Registrant's telephone number, including area code)

-------------------------------------------------------------------------------



Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]  Written  communications  pursuant to Rule 425 under the  Securities Act (17
     CFR 230.425)

[ ]  Soliciting  material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[ ]  Pre-commencement   communications  pursuant  to  Rule  14d-2(b)  under  the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement   communications  pursuant  to  Rule  13e-4(c)  under  the
     Exchange Act (17 CFR 240.13e-4(c))






ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
          APPOINTMENT OF PRINCIPAL OFFICERS


     On September  10, 2004,  Antigenics  Inc.  (the  "Company")  announced  the
appointment of Alastair J. J. Wood, MD, to its board of directors.  There was no
arrangement  or  understanding  pursuant  to which  Dr.  Wood was  elected  as a
director,  and there are no related party  transactions  between the Company and
Dr.  Wood.  Dr. Wood will serve on the  Corporate  Governance  Committee  of the
Company's Board of Directors.


     On September 10, 2004,  the Company  issued a press release  announcing the
election of Dr. Wood as a new director to the Company's Board of Directors.  The
full text of the press release is attached as Exhibit 99.1 to this Form 8-K.





ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS


         (c) Exhibits:

             99.1     Press Release dated September 10, 2004














                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          ANTIGENICS INC.

Date: September 10, 2004
                                          By: /s/ Garo H. Armen
                                          ----------------------------------
                                         Garo H. Armen, Ph.D.
                                         Chairman and Chief Executive Officer












EXHIBIT INDEX


The following designated exhibits are filed herewith:

Exhibits:

99.1              Press Release dated September 10, 2004